Regeneron Pharmaceuticals (REGN) News Today $580.70 +1.09 (+0.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$580.25 -0.45 (-0.08%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Regeneron Pharmaceuticals Up Today?Toggle Visibility of Why Is Regeneron Pharmaceuticals Up Today?Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have risen on the back of multiple clinical trial updates, an FDA approval, and analyst target upgrades. Key developments include: Positive Sentiment: Regeneron’s Phase 3 study on REGN7508 demonstrated potential as a breakthrough in thromboprophylaxis.Regeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in Thromboprophylaxis Positive Sentiment: Updated results from Regeneron’s heart failure trial hint at improved outcomes for patients.Regeneron’s Heart Failure Study: A Potential Game-Changer? Positive Sentiment: Phase 2 data on REGN’s blood clot prevention therapy show encouraging efficacy and safety signals.Regeneron’s Phase 2 Study on Blood Clot Prevention: A Potential Game-Changer? Positive Sentiment: Preliminary findings highlight the promise of pozelimab plus cemdisiran in treating PNH.Regeneron’s Innovative Approach: Pozelimab and Cemdisiran in PNH Treatment Positive Sentiment: Phase 2 ovarian cancer trial results suggest a promising new therapeutic option.Regeneron’s Promising Phase 2 Study on Ovarian Cancer Treatment Positive Sentiment: Early data from the linvoseltamab trial point to efficacy against resistant multiple myeloma.Regeneron’s Linvoseltamab Study: A New Hope for Resistant Multiple Myeloma Positive Sentiment: REGN7544 shows promise as a treatment for sepsis-induced hypotension in initial reports.Regeneron’s REGN7544: A Promising Treatment for Sepsis-Induced Hypotension? Positive Sentiment: Study on REGN7999 indicates potential for managing iron overload in beta-thalassemia patients.Regeneron’s Promising Study on REGN7999 for Iron Overload in Beta-Thalassemia Positive Sentiment: The FDA approved linvoseltamab for multiple myeloma, bolstering Regeneron’s oncology portfolio.FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma Positive Sentiment: Sanford C. Bernstein raised its price target from $753 to $781 and maintained an “outperform” rating.Sanford C. Bernstein Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Positive Sentiment: Jefferies lifted its target price from $813 to $831 and reiterated a “buy” rating.Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says Positive Sentiment: American Banking News set a new $781 price target via Sanford C. Bernstein’s upgrade.Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $781.00 Price Target at Sanford C. Bernstein Positive Sentiment: American Banking News also noted a $831 target based on Jefferies’ recommendation.Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $831.00 Price Target at Jefferies Financial Group Neutral Sentiment: Brokerages collectively set a consensus target price of $829.65 for Regeneron.Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $829.65 Neutral Sentiment: Wall Street analysts’ average target prices for Regeneron were summarized in a recent Yahoo Finance report.What Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock? Posted 1+ days agoAI Generated. May Contain Errors. REGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period The Manufacturers Life Insurance Company Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGNAugust 31 at 7:24 AM | marketbeat.comMagnetar Financial LLC Has $7.32 Million Stake in Regeneron Pharmaceuticals, Inc. $REGNAugust 31 at 7:15 AM | marketbeat.comTe Ahumairangi Investment Management Ltd Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNAugust 31 at 6:51 AM | marketbeat.comLansforsakringar Fondforvaltning AB publ Has $25.29 Million Stake in Regeneron Pharmaceuticals, Inc. $REGNAugust 31 at 5:52 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Position Trimmed by Tema Etfs LLCAugust 30 at 8:18 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Orion Investment CoAugust 30 at 6:54 AM | marketbeat.comKestra Advisory Services LLC Sells 1,835 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 30 at 4:32 AM | marketbeat.comWellington Management Group LLP Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGNAugust 30 at 4:13 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After SetbacksAugust 30 at 2:38 AM | uk.finance.yahoo.comRegeneron’s Phase 3 Study on REGN7508: A Potential Game-Changer in ThromboprophylaxisAugust 29 at 12:50 PM | tipranks.comRegeneron’s Heart Failure Study: A Potential Game-Changer?August 29 at 12:50 PM | tipranks.comRegeneron’s Phase 2 Study on Blood Clot Prevention: A Potential Game-Changer?August 29 at 12:50 PM | tipranks.comSanford C. Bernstein Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) StockAugust 29 at 11:02 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Jefferies Financial Group Analyst SaysAugust 29 at 8:41 AM | marketbeat.comGuggenheim Capital LLC Sells 4,547 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 29 at 7:36 AM | marketbeat.comComerica Bank Purchases 789 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 29 at 5:47 AM | marketbeat.comBrokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $829.65August 29 at 3:57 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $781.00 Price Target at Sanford C. BernsteinAugust 29 at 2:21 AM | americanbankingnews.comWhat Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?August 28 at 8:50 PM | finance.yahoo.comRegeneron’s Innovative Approach: Pozelimab and Cemdisiran in PNH TreatmentAugust 28 at 12:51 PM | tipranks.comRegeneron’s Promising Phase 2 Study on Ovarian Cancer TreatmentAugust 28 at 12:50 PM | tipranks.comRegeneron’s Linvoseltamab Study: A New Hope for Resistant Multiple MyelomaAugust 28 at 12:50 PM | tipranks.comRegeneron’s REGN7544: A Promising Treatment for Sepsis-Induced Hypotension?August 28 at 12:50 PM | tipranks.comRegeneron’s Promising Study on REGN7999 for Iron Overload in Beta-ThalassemiaAugust 28 at 12:50 PM | tipranks.comRafferty Asset Management LLC Reduces Position in Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 8:11 AM | marketbeat.comEpoch Investment Partners Inc. Acquires 10,190 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 8:09 AM | marketbeat.comCeredex Value Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 7:55 AM | marketbeat.comFORA Capital LLC Has $3.46 Million Position in Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 7:54 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Stake Boosted by Harvest Portfolios Group Inc.August 28 at 7:26 AM | marketbeat.comCorebridge Financial Inc. Sells 1,228 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 7:17 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Bought by Kayne Anderson Rudnick Investment Management LLCAugust 28 at 6:56 AM | marketbeat.comFDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple MyelomaAugust 28 at 6:31 AM | insidermonkey.com1832 Asset Management L.P. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 5:26 AM | marketbeat.comCW Advisors LLC Buys Shares of 1,428 Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 5:17 AM | marketbeat.comAlgert Global LLC Invests $288,000 in Regeneron Pharmaceuticals, Inc. $REGNAugust 28 at 4:01 AM | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Given New $831.00 Price Target at Jefferies Financial GroupAugust 28 at 3:47 AM | americanbankingnews.comRegeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer TreatmentAugust 27, 2025 | tipranks.comRegeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?August 27, 2025 | tipranks.comWhere Regeneron Pharmaceuticals Stands With AnalystsAugust 27, 2025 | benzinga.comWhat Are Wall Street Analysts’ Target Price for Regeneron Pharmaceuticals Stock?August 27, 2025 | barchart.comCaisse DE Depot ET Placement DU Quebec Sells 87,539 Shares of Regeneron Pharmaceuticals, Inc. $REGNAugust 27, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by MetLife Investment Management LLCAugust 27, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc.: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia GravisAugust 27, 2025 | finanznachrichten.deRegeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low SoonAugust 27, 2025 | msn.comThe FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)August 27, 2025 | msn.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from AnalystsAugust 27, 2025 | marketbeat.comRegeneron's rare immune disorder therapy meets main goal of late-stage trialAugust 26, 2025 | reuters.comRegeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia GravisAugust 26, 2025 | globenewswire.comRegeneron Pharmaceuticals, Inc. $REGN Shares Sold by APG Asset Management N.V.August 26, 2025 | marketbeat.comGroupe la Francaise Has $4.92 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGNAugust 26, 2025 | marketbeat.com Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Media Mentions By Week REGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼1.101.09▲Average Medical News Sentiment REGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼6434▲REGN Articles Average Week Get the Latest News and Ratings for REGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Gilead Sciences News Moderna News Intellia Therapeutics News Vir Biotechnology News Vertex Pharmaceuticals News AbbVie News Eli Lilly and Company News Merck & Co., Inc. News Pfizer News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REGN Stock Alerts